Yifan Pharmaceutical Co., Ltd.

Yifan Pharmaceutical Co., Ltd. saw a notable decline in its stock today, dropping significantly compared to the broader market. Over the past week, the stock has decreased substantially, while its annual performance remains modest. Financial metrics reveal challenges, including low returns and declining net sales over five years.

Yifan Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. While the company has experienced a monthly increase, its one-year performance lags behind the index. Financial metrics reveal challenges, including low returns and declining net sales over the past five years.

Yifan Pharmaceutical Co., Ltd. has seen a notable increase in its stock performance, with significant gains over the past week and month. Despite challenges in long-term growth and declining net sales, the company has reported positive results for the last five quarters, highlighting strong operating cash flow.

Yifan Pharmaceutical Co., Ltd. saw a notable intraday increase on March 10, 2026, outperforming the China Shanghai Composite. While the company has shown recent short-term gains and positive quarterly results, long-term growth metrics reveal challenges, including declining net sales and operating profit, alongside concerns about financial leverage.

Yifan Pharmaceutical Co., Ltd. has recently experienced a score adjustment due to changes in its technical indicators. The company faces challenges with a low Return on Capital Employed and declining net sales, yet it has reported positive operating cash flow for the last five quarters and maintains a notable dividend yield.

Yifan Pharmaceutical Co., Ltd. has seen a notable increase in its stock performance, gaining 5.82% on February 26, 2026, and achieving an intraday high of CNY 13.62. The company has reported positive results for five consecutive quarters, with strong operating cash flow and a significant market capitalization.